Stroke Center, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Eur J Med Res. 2022 Jun 3;27(1):83. doi: 10.1186/s40001-022-00705-z.
C-reactive protein (CRP) is an important biomarker of inflammation and plays a pivotal role in predicting the clinical prognosis of cardiovascular and cerebrovascular diseases. However, the mechanism of inflammation influencing the outcome of patients with ischemic stroke are unknown.
We aim to investigate the association between hsCRP and mRS in 194 eligible patients by therapy-stratified analyses.
The modification effects of antiplatelet therapy on the association between mRS and different exposure variables were analyzed. The retained variables were analyzed in the receiver operating characteristic (ROC) curve to discriminate patients with poor outcome.
hsCRP was positively correlated with mRS in therapy-stratified analyses. There was a statistical modification effect of antiplatelet therapy on the association of hsCRP and mRS (P for interaction = 0.0101). The discriminative effect of poor outcome was further verified by ROC curve analyses (AUC from 0.758 to 0.872, AUC from 0.709 to 0.713).
hsCRP is correlated with the clinical outcome of patients treated with IVrt-PA, and may be a better predictor of post-thrombolytic functional outcome in patients with previous antiplatelet therapy than in non-used patients.
C 反应蛋白（CRP）是炎症的重要生物标志物，在预测心血管和脑血管疾病的临床预后方面发挥着关键作用。然而，炎症影响缺血性脑卒中患者结局的机制尚不清楚。
通过治疗分层分析，旨在探讨 194 例符合条件的患者中 hsCRP 与 mRS 的相关性。
分析抗血小板治疗对 mRS 与不同暴露变量之间关联的修饰作用。保留变量在接收者操作特征（ROC）曲线中进行分析，以区分预后不良的患者。
hsCRP 在治疗分层分析中与 mRS 呈正相关。hsCRP 与 mRS 的关联存在抗血小板治疗的统计学修饰作用（交互作用 P=0.0101）。ROC 曲线分析进一步验证了不良结局的判别效果（AUC 从 0.758 到 0.872，AUC 从 0.709 到 0.713）。
hsCRP 与接受 IVrt-PA 治疗的患者的临床结局相关，并且在有抗血小板治疗史的患者中，hsCRP 可能比未使用抗血小板治疗的患者更能预测溶栓后功能结局。
